- Active not recruitingPHASE2
A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2
This study is testing a new drug, disitamab vedotin, for certain advanced cancers like head and neck, lung, ovarian, and endometrial cancer. It's for people whose cancer has a marker called HER2 and has already been treated. The study wants to see how well the new drug works and if it's safe.
For: Carcinoma, Non-Small-Cell Lung · Ovarian Neoplasms · Endometrial NeoplasmsUnited States · Australia · Canada - Active not recruitingPHASE3
Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2
This study looks at new treatments for bladder and related cancers that have spread. We want to see if combining two drugs, disitamab vedotin and pembrolizumab, works better than standard chemotherapy. It also checks for side effects.
For: Urothelial CarcinomaUnited States · Argentina · Australia - RecruitingPHASE2
A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
This study looks at new treatments for a type of bladder cancer called urothelial cancer. Researchers want to see if drugs called disitamab vedotin and pembrolizumab can help people whose cancer has spread or is hard to remove, and to check for side effects.
For: Urothelial CarcinomaUnited States · Argentina · Australia - RecruitingPHASE2
A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors
This study looks at a new combination of experimental drugs, disitamab vedotin and tucatinib, for advanced breast or stomach cancers that have a specific marker called HER2. It aims to see how safe and effective this treatment is, and what side effects it might cause.
For: Breast Neoplasms · Gastroesophageal Junction Adenocarcinoma · HER2 Low Breast NeoplasmsUnited States · Australia · Canada